Patents Assigned to Biofrontera Bioscience GmbH
-
Patent number: 12544443Abstract: The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.Type: GrantFiled: March 22, 2023Date of Patent: February 10, 2026Assignee: Biofrontera Bioscience GmbHInventor: Hermann Lübbert
-
Patent number: 12280146Abstract: The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.Type: GrantFiled: December 8, 2023Date of Patent: April 22, 2025Assignee: Biofrontera Bioscience GmbHInventors: Montserrat Foguet, Lars Möllmann
-
Patent number: 11642411Abstract: The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.Type: GrantFiled: August 23, 2018Date of Patent: May 9, 2023Assignee: BIOFRONTERA BIOSCIENCE GMBHInventor: Hermann Lübbert
-
Patent number: 11540981Abstract: The present invention relates to a nanoemulsion comprising at least one aqueous component and a carrier, wherein the carrier comprises at least one lipophilic component, at least one surfactant and at least one alcohol. The present invention further relates to a composition comprising said nanoemulsion and an active agent. In particular, the composition is present as a gel and the active agent is 5-aminolevulinic acid, a derivative, precursor and/or metabolite thereof. The invention further relates to the preparation of said nanoemulsion and/or composition and to their use for the treatment of dermatological diseases, virus-associated diseases as well as diseases associated with cell proliferation, in particular, tumor diseases and/or psoriasis. The present invention is further directed to the use of said nanoemulsion in cosmetics.Type: GrantFiled: December 21, 2007Date of Patent: January 3, 2023Assignee: BIOFRONTERA BIOSCIENCE GMBHInventor: Montserrat Foguet Roca
-
Patent number: 9708304Abstract: The present invention relates to novel crystal forms of 4-(6-ethoxy-1-methoxy-thioxanthene-9-ylidene)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal forms of 4-(6-ethoxy-1-methoxy-thioxanthene-9-ylidene)-1-methyl piperidine hydrochloride and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine hydrochloride as well as to the use of these salts for preventing or treating migraine or pulmonary hypertension.Type: GrantFiled: January 31, 2014Date of Patent: July 18, 2017Assignee: Biofrontera Bioscience GmbHInventors: Beate Schmitz, Hermann Luebbert
-
Publication number: 20110250239Abstract: The present invention concerns the pharmaceutical and cosmetic application of biocolloids, which originate from the mixture of a nanoemulsion and at least one water-soluble plant extract such as an extract from Mahonia aquifolium, wherein the biological effect of the plant ingredients is enhanced by the composition although the nanoemulsion does not function as a carrier system. The biocolloids are especially for the treatment and care of the skin.Type: ApplicationFiled: April 7, 2011Publication date: October 13, 2011Applicant: BIOFRONTERA BIOSCIENCE GMBHInventors: Hermann LUEBBERT, Montserrat Foguet ROCA, Mirella GWAREK
-
Publication number: 20090324727Abstract: The present invention relates to a nanoemulsion comprising at least one aqueous component and a carrier, wherein the carrier comprises at least one lipophilic component, at least one surfactant and at least one alcohol, characterised in that at least one alcohol has at least three carbon atoms. The present invention further relates to a composition comprising said nanoemulsion and an active agent. In particular, the composition is present as a gel and the active agent is 5-aminolevulinic acid, a derivative, precursor and/or metabolite thereof. The invention further relates to the preparation of said nanoemulsion and/or composition and to their use for the treatment of dermatological diseases, virus-associated diseases as well as diseases associated with cell proliferation, in particular, tumor diseases and/or psoriasis. The present invention is further directed to the use of said nanoemulsion in cosmetics.Type: ApplicationFiled: December 21, 2007Publication date: December 31, 2009Applicant: BIOFRONTERA BIOSCIENCE GMBHInventor: Montserrat Foguet Roca
-
Patent number: 7511064Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.Type: GrantFiled: April 19, 2006Date of Patent: March 31, 2009Assignee: Biofrontera Bioscience GmbHInventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
-
Publication number: 20060183905Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.Type: ApplicationFiled: April 19, 2006Publication date: August 17, 2006Applicant: BIOFRONTERA BIOSCIENCE GmbHInventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
-
Patent number: 7060711Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.Type: GrantFiled: October 25, 2002Date of Patent: June 13, 2006Assignee: Biofrontera Bioscience GmbHInventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon